Nektar Therapeutics

1. 1

   Election of Directors

   ManagementBoard: FOR

   To elect one director (Howard W. Robin) to a term expiring at the 2029 Annual Meeting.

2. 2

   Approval of an Amendment to Our Amended and Restated 2017 Performance Incentive Plan

   ManagementBoard: FOR

   To approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares authorized for issuance under the plan by 3,000,000 shares (post 1:15 reverse split basis).

   More detail

   This management proposal asks shareholders to approve a 3,000,000-share increase in the authorization under Nektar’s Amended and Restated 2017 Performance Incentive Plan (after giving effect to the 1:15 reverse split). Management frames the request as necessary to preserve the company’s ability to grant stock options, RSUs and other equity-based awards to attract and retain employees and directors and to align their incentives with long‑term stockholder value, particularly as the company advances rezpegaldesleukin into Phase 3 and invests in pipeline programs. The proposal is routine in form for biotech companies but is consequential given the company’s recent positive clinical readouts and significant financing activity in 2025–2026 that increase hiring, retention needs and dilution sensitivity. The board recommends a vote “FOR,” arguing that without additional shares the company’s ability to provide competitive equity compensation would be constrained and could impair recruitment and retention at a critical development milestone. Key plan features described include anti‑repricing protections (no repricing without shareholder approval), limits on per-person annual awards, full-value award counting at a 1.5x rate, performance‑based award flexibility, change‑in‑control treatment, and a termination date for new grants (March 27, 2027) absent earlier board action. The company discloses that all directors and executive officers are eligible for awards and thus have a personal interest in approval, and quantifies current outstanding awards and available shares as of the record date. For an analyst evaluating the proposal, important considerations include the size of the requested increase relative to existing headroom and expected hiring/grant needs for planned Phase 3 programs, the mechanics for counting full‑value awards (1.5x), governance protections (no repricing without shareholder approval), and potential dilution calculations tied to market capitalization. Overall, the proposal is typical of late‑stage development biotech companies scaling clinical development and hiring, and the board’s rationale centers on operational needs to sustain development momentum and retain talent; investors will weigh the benefit of incentivizing management and staff against incremental dilution and should assess the company’s historical burn of plan shares and the tightness of current share reserves.

3. 3

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   To ratify the Audit Committee’s selection of Ernst & Young LLP as Nektar’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

4. 4

   Advisory Vote on Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   A non-binding advisory vote to approve the compensation paid to the company’s named executive officers as disclosed in the proxy statement (a 'say-on-pay' vote).

   More detail

   This management-sponsored advisory proposal asks shareholders to endorse (on a non‑binding basis) the Company’s executive compensation program for named executive officers as disclosed in the proxy. Management frames the program around pay‑for‑performance principles, a mix of base salary, annual cash incentives tied to corporate and individual goals, and long‑term equity (time‑based and performance‑based RSUs and options) to align management with long‑term shareholder value. The proxy highlights significant 2025 milestones—positive Phase 2b results for rezpegaldesleukin, FDA Fast Track designations, initiation/preparation for Phase 3, and strengthened cash position—and ties compensation outcomes (annual bonuses and performance awards) to those achievements. The board recommends a “FOR” vote and commits to consider the advisory outcome when making future compensation decisions; it also discloses robust governance practices (independent compensation committee, independent consultant, clawback policy, anti‑hedging, stock ownership guidelines). For a sophisticated evaluator, key issues include (i) whether incentive targets and performance metrics are sufficiently rigorous and disclosed to assess stretch versus formulaic goals, (ii) the mix of time‑based versus performance‑based equity and the historical vesting outcomes (including canceled or unmet TSR‑based awards), (iii) pay outcomes relative to realized company performance and TSR, and (iv) any potential conflicts or departures from best practices (the company discloses standard protections such as no repricing without shareholder approval and clawbacks). Given the non‑binding nature of the vote, its principal utility is as feedback to the Organization and Compensation Committee; investors should review the detailed CD&A, peer benchmarking, and realized pay-versus-performance reconciliation presented in the proxy to form a view on whether the disclosed program and outcomes warrant endorsement.

Upcoming shareholder meetings at Nektar Therapeutics’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Nektar Therapeutics 2026 annual meeting?

Nektar Therapeutics (NKTR) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.

What is the record date for the Nektar Therapeutics 2026 meeting?

The record date for the Nektar Therapeutics 2026 meeting is Monday, April 6, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Nektar Therapeutics's 2026 meeting?

The board is presenting 1 director nominee at the Nektar Therapeutics 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Nektar Therapeutics 2026 meeting?

Shareholders will vote on 4 proposals at the Nektar Therapeutics 2026 meeting, each tagged with who proposed it and the board's recommendation.